Based on this evidence, Yu et al. aimed to prove that Src is an important downstream regulator of Cx32 in tumor cells and is associated with chemoresistance to doxorubicin, using HCC tissue samples and 54 and HepG2 cell lines, creating HepG2/DOX cell lines resistant to doxorubicin chemotherapy [68]. The gene discussed is GJB1; the disease is neoplasm.